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Abstract
Background: Mesenchymal Progenitor/Stem Cells (MSC) respond to homing cues providing an important mechanism 
to deliver therapeutics to sites of injury and tumors. This property has been confirmed by many investigators, however, 
the efficiency of tumor homing needs to be improved for effective therapeutic delivery. We investigated the feasibility 
of enhancing MSC tumor targeting by expressing an artificial tumor-binding receptor on the MSC surface.
Methods: Human MSC expressing an artificial receptor that binds to erbB2, a tumor cell marker, were obtained by 
transduction with genetically modified adenoviral vectors encoding an artificial receptor (MSC-AR). MSC-AR properties 
were tested in vitro in cell binding assays and in vivo using two model systems: transient transgenic mice that express 
human erbB2 in the lungs and ovarian xenograft tumor model. The levels of luciferase-labeled MSCs in erbB2-
expressing targeted sites were evaluated by measuring luciferase activity using luciferase assay and imaging.
Results: The expression of AR enhanced binding of MSC-AR to erbB2-expressing cells in vitro, compared to unmodified 
MSCs. Furthermore, we have tested the properties of erbB2-targeted MSCs in vivo and demonstrated an increased 
retention of MSC-AR in lungs expressing erbB2. We have also confirmed increased numbers of erbB2-targeted MSCs in 
ovarian tumors, compared to unmodified MSC. The kinetic of tumor targeting by ip injected MSC was also investigated.
Conclusion: These data demonstrate that targeting abilities of MSCs can be enhanced via introduction of artificial 
receptors. The application of this strategy for tumor cell-based delivery could increase a number of cell carriers in 
tumors and enhance efficacy of cell-based therapy.
Background
In the last few years, cells have been increasingly used as
vehicles for the delivery of therapeutics. The cell-based
approach is particularly attractive for the delivery of bio-
therapeutic agents that are difficult to synthesize, have
limited tissue penetrance, or are rapidly inactivated upon
direct in vivo introduction. Some of the key factors for
the success of this type of therapeutic delivery have been
established, such as the means and efficiency of cell load-
ing with a therapeutic payload, and the nature of thera-
peutics that the cells can carry. However, the issue of
biodistribution of injected cell carriers in vivo still
remains an important aspect of cell-based delivery that
has yet to be fully investigated. Importantly, different
types of cell vehicles may have specific biodistribution or
cell homing patterns and, therefore, may provide a special
advantage to achieve site-specific or targeted delivery of
therapeutics.
The ability of injected cells to either passively concen-
trate in specific organs or actively home to disease sites
supports the rationale for targeted delivery of therapeu-
tics by cell vehicles. There is growing evidence that sites
of injury or growing tumors favor active homing of
endogenous and exogenous stem or progenitor cells [1,2].
The first observation of this phenomenon was published
by Studeny et al, using MSCs as vehicles delivering IFNβ
[3]. This and a subsequent study by the same group [4]
reported MSC localization in lung tumors after systemic
injection of these cells. The recognition that the tumor
microenvironment or tumor cytokine profile is similar to
that of inflammatory sites evoked a search for the tumor
attracting signals. Despite still incomplete knowledge of
these cues, the practical aspects of cell-based delivery of
therapeutics to specific sites have been actively exploited.
A  g r o w i n g  n u m be r  o f  s t u d i e s  h a v e  u s ed  M S C s  a s  c e l l
vehicles to exploit their native ability to target tumors, as
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a means to track malignant tissues or for the delivery of
anticancer agents to tumors [2,5-9]. Several studies inves-
tigated MSCs as cell vehicles for the delivery of various
clinically relevant anticancer factors, including cytokines,
interferons, pro-drugs and replication competent adeno-
viruses, with noted benefits [10-13]. The native tumor
homing phenomenon of MSCs was confirmed in differ-
ent experimental systems [2,12]. Other cell types, such as
umbilical cord matrix stem cells (UCMS) [14], neural
stem cells [15,16] and endothelial progenitor cells [17,18]
have also demonstrated the inherent ability to migrate
toward tumors or other pathologies.
Along with using native cell homing properties, modifi-
cation of the cell membrane by expressing appropriate
receptors was also proposed as a means to obtain tar-
geted cell vehicles. Much of the groundwork for such tar-
geting approaches has previously been established for
immune cells (T-cells, NK cells, CIK cells), where lym-
phocyte populations were modified to express artificial
receptors (T-bodies) with distinct binding specificities to
target cells. Artificial or chimeric receptors (AR) have
been derived from the binding domains of antibodies
(usually the single chain antibody, scFv) or T-cell recep-
tors. An array of chimeric receptors, mostly with specific-
ity for different tumor markers, has been tested for
biological function in vitro [19,20] and in vivo [21,22].
This approach is often termed "targeted" adoptive immu-
notherapy, since the active targeting mechanism was
added to redirect the native killing function of an
immune cell to a defined target cell. Remarkably, the
added affinity to retarget cell killing function was found
to enhance localization of the modified cells to the target
sites. Several studies demonstrated that AR-modified
lymphocytes are detected in higher numbers in tumors
that express the cognate receptor, compared to untar-
geted cells [23,24].
Despite showing its potential, the AR-based strategy
has not been translated to other cell types that may serve
as promising cell vehicles. Only a few applications have
demonstrated the feasibility of using AR as a binding
moiety in non-immune cell contexts [25,26]. In other
examples, surface-expressed scFvs served as artificial
receptors for viral infection [27] or enhanced the tumor
cell binding [28]. Therefore, applying the AR strategy to
other cell types and investigating the potential targeting
benefits holds promise as a means to increase cell con-
centration in desired sites. Of note, most of the studies
using native MSC homing did not quantitatively deter-
mine the level of cells that home to tumors or other sites.
The tumor homing behavior of MSCs was demonstrated
by the mere presence of these cells in the sites of interest
and/or lack of such cells in other organs [8,11,13,29]. The
few studies that did attempt to quantitatively estimate
MSC numbers localized in tumors have reported low to
moderate numbers [3,5,10]. Since increasing the number
of cell vehicles in tumors would parallel therapeutic effi-
cacy, investigation of native or artificial means of cell
homing to tumors are of high therapeutic importance.
The present study tested the hypothesis that artificial
receptors with affinities to target sites can be added to
cell vehicles and the new cell binding properties can be
utilized to increase cell vehicle levels in the target sites.
Specifically, we investigated the possibility of increasing
the number of MSCs in ovarian tumors by expressing a
tumor antigen-binding receptor on the MSC surface.
This would provide an additional means to increase the
number of tumor-associated MSCs beyond their native
t u m o r  h o m i n g  po t e n t i a l .  T o  t h i s  e n d ,  w e  h a v e  cr e a t ed
MSCs that express an artificial receptor (AR) that binds
to erbB2, a frequent marker of tumor cells (MSC-AR). We
have shown that these AR-expressing MSCs (MSC-AR)
have enhanced binding to erbB2-expressing cells in vitro.
Furthermore, we tested erbB-2 targeting of MSC-AR in
model systems in vivo and demonstrated that addition of
the AR increased retention of circulating MSC-AR in
erbB2-expressing sites. We also confirmed an increased
concentration of MSC-AR, compared to MSC, in erbB2
positive ovarian tumors.
These data show that the number of tumor-associated
MSCs can be increased via affinity-based targeting,
which can potentially serve to improve therapeutic deliv-
ery. Broadly, we demonstrated that an artificial cell tar-
geting strategy can be beneficial to MSC-based cell
vehicles and suggests that this strategy could also have
potential for other cell types that lack native homing abil-
ities.
Methods
Reagents
Anti-HA antibody conjugated to horse radish peroxidase
(HRP) clone HA-7 (Sigma, Saint-Louis, Missouri) was
used for detection of artificial receptor expressed on
MSCs membrane. Anti-erbB2 (HER-2/neu) antibody,
clone AM-2000-01 (Innogenex, San Ramon, CA) was
used to test expression of the erbB2 protein. Goat anti-
mouse IgG1 (HRP conjugated) was used as a secondary
antibody (DAKO corporation, Carpinteria, CA). CFDA-
CE and SP-DiI fluorescent dyes (green and red fluores-
cence correspondingly) for cell labeling were from
Molecular Probe (Eugene, OR).
Cell lines
The human ovarian carcinoma cell line SKOV3ip1 was
obtained from Dr. Janet Price (University of Texas M.D.
Anderson Center, Houston, TX). K562 cells - were
obtained from ATCC the American Type Culture Collec-
tion (Manassas, VA) and cultured as recommended. Cells
were maintained in DMEM/F-12, containing 10% fetalKomarova et al. Journal of Ovarian Research 2010, 3:12
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bovine serum (FBS) (HyClone, Logan UT) and 2 mM glu-
tamine at 37°C in a humidified atmosphere of 5% CO2.
Isolation and culture of MSCs
Primary human MSCs were obtained from bone marrow
draw leftovers (screen filters with bone marrow cells
remaining) from several individuals undergoing bone
marrow harvest for allogeneic transplantation at the UAB
Stem Cell Facility under an approved IRB protocol. MSCs
were isolated and cultured as previously described [30].
Cells were expanded by consecutive subcultivations in α-
MEM with 10% FBS at densities of 5000-6000 cells/cm2
and used for experiments at passages 2-8.
Recombinant adenoviruses
Adenoviral vectors having either wild type or genetically
modified Ad5 fibers were used for experiments to load
MSC with the targeting moiety and reporter genes. The
following viruses were used in the study: AdCMV.AR,
Ad.RGD.AR, Ad.RGDpK7.ARluc, Ad.RGDpK7.GFPluc.
All viruses were replication-incompetent recombinant
adenoviral (Ad) vectors having either single transgene or
double cassette of transgenes in the E1 region under con-
trol of two CMV promoters. Coding sequences of AR,
firefly luciferase and GFP were amplified by PCR from
the plasmids pDisplayAR, pGL3 (Promega, Madison, WI)
and pTrack (Qbiogene, Solon, OH) correspondingly and
cloned into pShuttle plasmid.
AdCMV.AR has a wild type Ad5 fiber; AdRGD.AR has a
fiber protein with an integrin binding motif (CDCRGD-
CFC) inserted in the HI loop [31]; both AdRGDpK7 vec-
tors have a pK7 peptide at the C-terminus of fiber in
addition to the RGD motif. Viral genomes were obtained
by recombination of the corresponding pShuttle and Ad
backbone plasmid in bacteria as previously described
(QBiogen, Adenovator manual). All viruses were con-
structed and tested at the UAB Gene Therapy Center.
The lentiviral vector used in the study to obtain K562-
erbB2 was constructed as described previously [32]. The
plasmids for self-inactivating lentiviral vector were kindly
provided by Dr. D.B. Kohn (Children's Hospital, Los
Angeles). Resulting lentiviral vector contained an internal
MND (Myeloproliferative sarcoma virus enhancer, Nega-
tive control region Deleted) promoter [33], human c-
erbB2 cDNA and the central polypurine tract/central ter-
mination sequence. The c-erbB2 coding sequence (Gene
Bank NM_004448) was amplified by PCR from the plas-
mid pGT36erbB2 that was kindly provided by Dr. T.
Strong (UAB). The virus was generated as described by
Zielske et al [32].
Design of transiently targeted and labeled MSC-AR
MSC-AR were obtained by transduction of MSCs with
adenoviral vectors encoding the artificial receptor (AR).
The artificial receptor to target MSC to ovarian carci-
noma was first constructed using the pDisplay mamma-
lian expression vector (Invitrogen, Carlsbad, CA) that
allows display of proteins on the cell surface. An anti-
erbB2 scFv C6.5 [34] as binding motif was fused at the N-
terminus to the murine Ig κ-chain leader sequence and at
the C-terminus to the platelet derived growth factor
receptor (PDGFR) transmembrane domain. Recombinant
AR contains the hemagglutinin A (HA) and myc epitopes
for detection by Western blot. AR cDNA was then trans-
ferred to adenoviral vectors and these vectors were used
t o  o b t a i n  M S C  e x p r e s s i n g  A R  o n  t h e  c e l l  m e m b r a n e
(MSC-AR). For all in vitro and in vivo experiments MSCs
were transduced with adenoviral vectors as described
previously [30] at MOI 500 vp/cell. Membrane expression
of AR was confirmed by Western blot or immunohis-
tochemistry using an anti-HA tag antibody following
development with Nova-Red or DAB as HRP substrates.
MSCs expressing scFv C6.5 with anti-erbB2 specificity
are labeled throughout the text as MSC-AR. MSC trans-
duced with isogenic viral vector AdRGDpK7.GFPluc
were used as an appropriate counterpart for AR -trans-
duced cells in all experiments and labeled as MSC-GFP.
Both recombinant Ad vectors (AdRGDpK7.C6.5luc and
AdRGDpK7.GFPluc) for ex vivo MSC transduction have
luciferase gene in the context of double expression cas-
settes: GFPluc and C6.5luc. This simultaneous loading of
the transgene with a luciferase reporter allows the use of
luciferase expression for quantitative comparison of
MSC-AR and MSC targeting.
In vitro cell-cell interaction assays
MSC-SKOV mixed assay. Binding properties of MSC-AR
were tested using SKOV3ip1 cells that abundantly
express erbB2. MSCs and MSC-AR were labeled with the
green fluorescent dye CFDA, whereas the SKOV3ip1
cells were labeled with the red dye SP-DiI according to
the reagents' manuals. Labeled cells were lifted with
Versene, washed and counted. MSCs and SKOV3ip1 were
mixed in different ratios in 300 μl of PBS at 500,000 total
cells/sample and incubated in solution under agitation.
After washing, cell populations were separated by flow
cytometry and the percentage of double-labeled cell pop-
ulation that corresponded to MSC-SKOV conglomerates
was determined by gating on the GFP-PE population.
MSC-K562 ELISA-based assay. K562 are non-adherent
cells and allow the possibility to perform ELISA-like anal-
ysis of cell-cell interaction. MSC-AR in vitro binding was
tested using K562 cells that artificially express erbB2.
K562 expressing erbB2 were obtained via lentiviral trans-
duction. To test cell-cell interaction, the suspensions of
K562 or K562-erbB2 labeled with a green fluorescent dye
(CFDA) were added to MSCs or MSC-AR cultured on a
plastic. After 1 hr incubation, K562 cells were washed out
and all cells in the wells were trypsinized. The cell mix-
ture was subjected to flow cytometry and the percentage
of bound fluorescent cells was determined in each well.
Each experimental group was assayed in triplicates.Komarova et al. Journal of Ovarian Research 2010, 3:12
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In vivo testing of targeted MSC
Transient transgenic model. To create a state of transient
expression of erbB2 in mouse lungs, we injected h-CAR
transgenic mice [35] with AdCMVerbB2 i.v. Expression of
the antigen in the lungs of these mice was confirmed by
Western Blot of lung lysates stained with an anti-erbB2
antibody. MSC-GFP and MSC-AR labeled with firefly
luciferase were injected i.v. in erbB2-preconditioned
hCAR mice at 1x106 cell/mouse. Mice were followed after
MSC injection by live non-invasive imaging at several
time points. Upon sacrifice, luciferase expression was
measured by imaging of the whole animal, imaging of the
excised lungs and by luciferase expression analysis of lung
lysates. To compare MSC numbers in the lungs and com-
pensate for potential differences in luc expression in
injected samples of targeted and untargeted MSC, the
amount of RLU/cell was calculated for MSC-GFP and
MSC-AR.
Ovarian xenograft model. Female CB17 SCID mice
(Charles River, Boston, MA) 6-8 weeks of age were used
to establish human ovarian xenografts. Intraperitoneal
tumors were established in mice by i.p. injection of 5x106
SKOV3ip1 cells. After 14 days of tumor development,
mice received intraperitoneally MSC-GFP or MSC-AR at
2x106  cells/injection. At designated time points after
MSC injection, mice were subjected to non-invasive
imaging for luciferase expression. The animals were sub-
sequently sacrificed; tumor nodules, liver, spleen, kidney
and part of the intestine were collected, imaged in a Petri
dish and proceeded to prepare tissue lysates for conven-
tional luciferase analysis. All visible tumor nodules in the
peritoneum were collected for imaging and combined as
one tumor sample for luciferase analysis.
Animal protocols were reviewed and approved by the
Institutional Animal Care and Use Committee of UAB.
Imaging and Quantification of Bioluminescence Data
An in vivo optical imaging was performed with a custom-
built optical imaging system with a liquid-nitrogen
cooled lKB digital CCD camera (Princeton Instruments
VersArray: Roper Scientific, Trenton, NJ). Mice were
anesthetized with 2% isoflurane before intraperitoneal
injection of d-luciferin. D-luciferin potassium salt, the
substrate for firefly luciferase, was purchased from
Molecular Imaging Products (Ann Arbor, Michigan).
Each mouse received an injection of 2.5 mg of d-luciferin
diluted in 100 μl of PBS. Mice (3 animals per group) were
placed in the supine position within the imaging chamber
with continuous isoflurane sedation. Whole body lumi-
niscent images were obtained during the 5-10 min inter-
val after injection of the substrate. Luminescence images
and brightfield images were acquired with an exposure
time of 60 and 0.02 sec respectively using WmView/32
software (Roper Scientific) without a filter at f/16. Index
color image overlays were performed in Photoshop 7. 0
(Adobe, Seattle, W A). The range of acquisition signal
was kept constant at all imaging time points. The gray
scale photographic images and bioluminescence color
images were superimposed using the Adobe Photoshop
7.0 software. Statistics on bioluminescent signal intensity
was obtained using WinView software according to the
software instruction. For comparison of tumor targeting
of two cell populations, total intensity of bioluminescence
signal acquired from collected tumors were normalized
per tumor area. Obtained value of relative light units per
area (RLU/cm2/min) is proportional to the number of
cells present on tumor surfaces.
Luciferase expression in tissue lysates
Tumors and selected organs (liver, spleen, intestine, kid-
ney) after imaging were used to prepare tissue lysates.
Organs collected after sacrifice were homogenized using
Mini Beadbeater (BioSpec Product Inc) in 500 ul of 1x tis-
sue/cell lysis buffer (Promega). Luciferase expression in
tissue lysates was determined using luciferase assay sys-
tem (Promega, Madison, WI) according to the manufac-
turer protocol. The luciferase activities were measured in
a Lumat LB 9507 luminometer (Lumat, Wallac, Inc.,
Gaithersburg, MD) in relative light units (RLU) and nor-
malized by the protein concentration in cell or tissue
lysates (Bio-Rad DC Protein Assay kit). To account for the
potential differences in luciferase expression of the
injected MSC populations (targeted and untargeted), we
normalized tumor luciferase activity (RLU) by luciferase
activity of the MSCs (RLU/cell) and presented data as
MSC numbers per mg protein.
All in vivo data are presented as mean values ± standard
deviation. Statistical differences among groups were anal-
ysed in a two-tailed Student's t-test using GraphPad
Prizm Software (San Diego, CA).
Results
Design of MSC targeted to tumor markers by additional 
affinity
Although MSCs have the native ability to home to
tumors, we attempted to enhance their tumor-targeting
abilities by adding an additional tumor-targeting element:
an artificial receptor (AR) with specificity to erbB2 (Fig.
1 A ) .  Ex p r e s s i o n  o f  t h is  AR  o n  t h e  c e l l  m e m b r a n e  was
obtained by transduction of cells with adenoviral expres-
sion vectors. We had previously established that adenovi-
ruses with modified fibers have increased MSC
transduction, in particular those with RGDpK7 knob
modifications [12]. Thus, Ad vectors with the RGDpK7-
modified fiber were constructed in this study for AR
expression. The efficiency of MSC transduction by
AdRGDpK7 vectors in our experimental conditions was
tested by flow cytometry for GFP transgene (data notKomarova et al. Journal of Ovarian Research 2010, 3:12
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shown) and by immunostaining for AR expression (using
HA expression tag). Transduction with escalating MOIs
(20-500 vp/cell) resulted in progressively increasing num-
ber of infected cells. The level of 88-95% of AR-express-
ing cell was routinely achieved when 500 vp/cells were
used (Fig. 1B), thus this MOI was then consistently used
t o  o b t a i n  M SC - A R  f o r  a l l  i n  vi t r o  a n d  i n  v i v o  e x pe r i -
ments. Furthermore, for each individual experiment the
levels of expression of both transgenes (AR and luc) were
checked to assure that comparable cell populations were
used for different experiments and to minimize the
experimental variations due to variable AR expression.
Although fiber-modified Ads allowed sufficient efficiency
of MSC transduction, the level of AR expression on indi-
vidual cell (determined as intensity of staining) was vari-
able, which may reflect heterogeneity of MSC population
as it was noted previously.
In addition, a double expression cassette incorporated
into Ad vectors allowed simultaneous loading of MSCs
with a targeting moiety and a reporter gene for MSC
detection in vivo. Two Ad vectors were created for our
studies: Ad.RGDpK7.AR.Luc and Ad.RGDpK7.GFP.Luc.
MSC transduction with Ad.RGDpK7.AR.Luc enabled us
to obtain erbB2-targeted luc-labeled MSCs (MSC-AR) to
further test our strategy in vitro and in vivo. As an appro-
priate counterpart to MSC-AR, we used cells transduced
with an isogenic Ad vector, in which AR gene in double
cassette was substituted by GFP. These cells are labeled
MSC-GFP throughout the text.
MSC-AR bind to erbB2-expressing cells in vitro
To investigate if MSC-AR acquired new binding proper-
ties, we tested their erbB2-binding abilities in vitro in
cell-cell binding assays. The SKOV3ip1 ovarian tumor
cell line expresses high levels of erbB2, and was, there-
fore, used to test MSC-AR binding. MSC, MSC-AR, and
SKOV3ip1 were labeled with different fluorescent dyes
CFDA-CE (green) and SP-DiI (red) respectively. Both
MSCs and SKOV3ip1 cells are highly adherent to plastic;
therefore, binding interactions were performed in solu-
tion after cell dissociation with Versene. Cell interaction
resulted in the formation of small aggregates, which were
detected as a double-positive (CFDA-SP) population by
flow cytometric analysis. Increasing ratios of MSC-AR:
SKOV3ip1 cells consistently resulted in increased per-
centages of the double-positive population (39.5% at ratio
1:9, and 51% at ratio 1:3); this was in contrast to a control
mixture (MSC and SKOV3ip1), where the double-posi-
tive population never exceeded 8% (Fig. 2A). Similar
results were obtained in an ELISA-like assay, using non-
adherent K562 cells. To render K562 cells positive for
erbB2, the K562 cells were stably transduced with a lenti-
viral vector encoding erbB2. In this ELISA-like assay,
MSCs and MSC-AR were attached to the plastic in 12-
well plates to which K562 or K562-erbB2 cells labeled
with a green fluorescent dye were added. After sequential
washing, all cells in the wells were trypsinized and sub-
jected to FACS analysis to determine the number of
bound fluorescent cells. In accord with the previous
Figure 1 Design of MSC-AR targeted to tumor marker. A) Schematic presentation of Artificial Receptor C6.5 (AR) used to obtain MSC-AR and ge-
nomes of adenoviral vectors for AR expression. B) Genetically modified adenoviral vectors provided efficient expression of AR on MSC membrane. MSC 
were transduced with Ad.AR or AdRGDpK7.AR at MOI 500 vp/cell. AR expression on MSC membrane was confirmed by staining cells with a-HA tag 
antibody. MSCs expressing AR are stained red.Komarova et al. Journal of Ovarian Research 2010, 3:12
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experiment, the highest binding (30.7%) was detected in
wells with MSC-AR and K562-erbB2 cells (Fig. 2B).
Therefore, both in vitro assays confirmed that MSC-AR
efficiently bind to erbB2 expressing cells.
MSC-AR bind to erbB2-expressing cells in vivo
Differential kinetics of MSC lung clearing in a 
transient transgenic model We next investigated if
membrane expression of the AR could be translated to in
vivo cell targeting advantages. We first tested our hypoth-
esis using a transient transgenic model system, in which
the erbB2 marker was artificially expressed in mouse
lungs. This transient transgenic mouse model was previ-
ously used to confirm the targeting benefits of affinity-
modified adenoviral vectors [36]. A transgenic mouse
strain expressing the receptor for human adenovirus,
hCAR [35] enables efficient infection of mouse tissues
with human adenovirus. Intravenous injection of Ad vec-
tors into the hCAR mice results in increased expression
of Ad-delivered transgenes in the mouse lungs, compared
to wild type C57Bl6 mice, in which 90% of the adenoviral
transgene expression is detected in the liver [37,38]. This
model, therefore, allows human tumor markers to be
expressed in lungs, where this marker is readily accessible
to systemically introduced cells. Transient expression of
the erbB2 tumor marker in the lungs of hCAR transgenic
mice was achieved by i.v. injection of an adenovirus
encoding the erbB2 antigen (AdCMVerbB2). Expression
of erbB2 exclusively in the lungs of the hCAR(+) mice
compared to other organs was detected, as shown by a
Western blot stained with anti-erbB2 antibodies (Fig.
3A). Injection of the same Ad vector into hCAR(-) litter-
mates and SCID mice did not result in detectable expres-
sion of erbB2 in the lungs (data not shown). Thus, the
transient transgenic model proved to be appropriate to
test the effect of erbB2-lung targeting with AR-expressing
MSCs.
Both MSC-GFP and MSC-AR injected i.v. first localize
to the lungs due to first pass effect [39]. Thus, we did not
expect to see differences at initial time points after cell
injection. We wanted to evaluate differential kinetics of
cells retention in the lungs as a measure of cell-cell inter-
action achieved by MSC-AR in vivo (Fig. 3B-E). Since the
kinetics of this process was unknown, two experiments
were carried out to investigate early (Fig. 3B, D) and late
(Fig. 3C, E) time points.
The first experiment covered early time point including
4, 8, 14, 24 hrs after cell injection. Luciferase activity was
measured by the intensity of the chemiluminescent signal
in excised lungs and by conventional luciferase assays
using whole lung lysates. To compensate for potential dif-
ferences in the levels of luciferase expression in the
injected samples of MSC-GFP and MSC-AR, the value of
Figure 2 MSC-AR bind to erbB2-expressing cells in vitro. A) MSC-SKOV mixed assay. MSC and MSC-AR labeled with green fluorescent dye CFDA 
were mixed with SKOV3ip1 cells labeled with red dye SP-DiI. After incubation in solution, cell populations were separated by FACS and percent of 
double-labeled population that corresponded to MSC-SKOV conglomerates was determined by gating on GFP-PE population in FACS analysis. B) 
MSC-K562 ELISA-based assay. K562 expressing erbB2 were obtained via lentiviral transduction. MSC or MSC-AR were cultured attached to plastic. Sus-
pension of K562 or K562-erbB2 labeled with green fluorescent dye (CFDA) were added to cultured MSC-AR. After 1 hr incubation K562 cells were 
washed out and all cells in the wells were trypsinized. Cell mixture was subjected to FACS and percentage of bound fluorescent cells was determined 
in each well. Each group was done in triplicates.Komarova et al. Journal of Ovarian Research 2010, 3:12
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RLU/cell for each cell sample was calculated. The statisti-
cally significant differences in MSC and MSC-AR num-
bers were detected at 14 hrs and 24 hrs after MSC
injection by both methods of luciferase detection: inten-
sity of the lung imaging signal (Fig. 3B) and luciferase
activity in lung lysates (Fig. 3D)
To trace the fate of injected cells further, we repeated
the experiment including more distant time points (24,
32, 50, 70 hrs). In this experiment an increased concen-
tration of MSC-AR in the lungs was detected starting at 8
hrs and persisted until 32 hrs after cell injection. This
trend was visualized using total body images (Fig. 3C) as
well as quantitatively measured by the luciferase activity
in lung lysates (Fig. 3E). This effect was only transient in
nature, as luciferase expression measured at the last time
points (50, 72 hrs) returned to almost background levels.
However, we were able to demonstrate the differences in
behavior of MSC-GFP and MSC-AR injected i.v. in erbB2
expressing animals. Since both experimental groups were
otherwise identical, we attribute these differences to the
newly added affinity property of MSC-AR that interacted
with erbB2-expressing cells.
Targeted MSC increase binding to erbB2-expressing 
ovarian tumors We have previously tested MSC homing
to ovarian tumors using the SKOV3ip1 ovarian tumor
xenograft model, where preferential homing of MSC to ip
tumors was demonstrated, compared to other organs in
the peritoneal cavity [12]. In this study we investigated if
MSC concentrations in tumors are increased via expres-
sion of the tumor-specific AR on the transplanted MSCs.
Figure 3 MSC-AR bind to erbB2-expressing lung cells in vivo in transient transgenic model. (A) Transient expression of erbB2 in the lungs of 
hCAR mice was induced by iv injection of AdCMVerbB2. Expression of erbB2 exclusively in the lungs of hCAR mice were confirmed by Western Blot 
of organ lysates. Lane M is Marker, lane SK - erbB2 positive control (SKOV3ip cell lysate), lane Lu - lung lysate, next lanes, labeled Sp, He, Li, Ki and Ov 
represent spleen, heart, liver, kidney, and ovary lysates correspondingly. Small triangle points to the size of erbB2-specific signal. (B-E) Kinetics of MSC-
GFP and MSC-AR distribution to the erbB2-lungs of hCAR mice. MSC-GFP and MSC-AR labeled with firefly luciferase were injected iv in erbB2-precon-
ditioned hCAR mice at 1x106 cell/mouse. In the first experiment (B, D) mice were followed at early time points after injection (4, 8, 14, 24 hrs), in the 
second experiment (C, E) later time points (24, 32, 50, 70 hrs) were investigated. Luciferase expression was detected by imaging of whole animal (C) 
imaging of excised lungs (B) and by luciferase expression analysis of lung lysates (D,E). Data are presented as number of cells per mg of protein in lung 
lysates. *-P = 0.05, ** - P = 0.01.Komarova et al. Journal of Ovarian Research 2010, 3:12
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SKOV3ip1 ovarian tumor xenografts abundantly express
erbB2, which was confirmed by erbB2 staining of tumor
xenografts (Fig. 4A). Results from the previous experi-
ment suggested that the kinetics of homing is the impor-
tant parameter to investigate. Thus, we again conducted
two experiments, in which the MSC numbers in tumors
were assessed at different times after injection.
In a pilot experiment, tumors were collected 24 hrs
after ip injection of MSC-GFP and MSC-AR and
luciferase expression was measured in tumor lysates (Fig.
4B). The estimated number of MSC-AR in erbB2 express-
ing tumors was 117073 ± 108375 cells/mg protein, while
the MSC-GFP was 14239 ± 6402 cells/mg protein. The
difference the in average numbers of AR-expressing ver-
sus AR-lacking cells in tumors was substantial (8.2 folds),
however, due to one tumor sample in MSC-AR group
with an outstanding RLU value, it was rendered statisti-
cally insignificant by t-test analysis.
To confirm this initial observation and to investigate
the kinetics of cell accumulation in tumors, we conducted
another experiment with a broader time line, which
included evaluation of cell numbers in tumors at 2, 6, 24,
and 48 hrs after MSC injection (Fig. 5). MSC-GFP and
M S C - A R  t u m o r  t a r g e t i n g  a s  w e l l  a s  b i o d i s t r i b u t i o n  t o
other organs was evaluated by measuring luc expression
in tumors and other major organs of the peritoneal cavity
(Fig. 5 and 6). At the indicated time points we also per-
formed whole body bioluminescent imaging, imaging of
individual organs after animal sacrifice, and analysis of
luciferase expression in organ lysates by conventional luc
assays.
Whole body imaging typically revealed discrete zones
of luciferase activity in the peritoneum, starting from the
earliest time point (2 hrs) tested. The signal has a more
diffuse pattern at 2 hours after cell injection, compared to
the more localized pattern observed at 24 hrs in both
groups (data not shown). The whole body imaging signal
approximated tumor localization, however, quantitation
of the signal in whole body images (thus, comparison of
MSC and MSC-AR tumor homing) was not performed,
as initially planned. We noted that the signal intensities in
the whole body images were greatly influenced by body
positioning, tumor localization in the cavity, and the
extent of tumor masking by other organs.
To attribute the obtained signals to particular organs,
excised tumors and organs of peritoneal cavity were
imaged separately in a Petri dish. MSC biodistribution to
these organs was quantitatively assessed by measuring
the bioluminescent signal intensities of individual organs
and luciferase activity in corresponding tissue lysates. In
both groups tested, this analysis demonstrated a clear
tumor preference of injected MSC (Fig. 5B). As early as 2
hrs after injection MSCs were detected in ovarian xeno-
grafts (Fig. 5A, C). Tumors were the major MSC targeting
site across all time points tested in both groups, with the
highest luciferase activities detected compared to the
ones in other organs. This was confirmed qualitatively by
detecting the luciferase signal in individual organs (Fig.
5B) and quantitatively by measuring luc activity in whole
organ lysates (Fig. 6).
The intensity of the signal in tumors grew over time,
reached its maximum at 24 hrs, and declined at 48 hrs
(Fig. 5A, C). We did not detect differences among tumor
luciferase activities in both groups at 2 and 6 hrs. How-
ever at 24 and 48 hrs, the mice that received MSC-AR
demonstrated higher luciferase activity in tumors by both
detection methods: tumor imaging (Fig. 5A) and
luciferase activity of tumor lysates (Fig. 5C). These data
are in concordance with the initial experiment, where we
detected considerable differences between MSC-GFP and
MSC-AR groups at 24 hrs. In the second experiment, the
difference between targeted and untargeted MSC
detected at this time was not as pronounced as in the
pilot experiment (211744 ± 178135 and 91023 ± 84675
cells/mg protein), and corresponded only to 2.3 times dif-
ference. The means and the standard deviation range was
affected by the small number of animals and individual
variations between tumor samples, and rendered this dif-
ference insignificant in t-test. But, the trend of an
i n c r e a s e d  n u m b e r  o f  M S C - A R  i n  t u m o r s  w a s  c l e a r l y
detected. The increased MSC-AR numbers detected in
tumors indicate increased specificity of MSC-AR tumor
targeting. At early time points the MSC-GFP group
showed relatively higher luciferase activities in other
organs, such as spleen, liver, and intestine, compared to
the organs of mice that received MSC-AR (Fig. 6). The
ratio of MSC numbers in tumor versus MSC number in
liver at 24 hrs was 153 for MSC-AR and 56 for MSC (Fig.
Figure 4 MSC-AR increase binding to erbB2-expressing ovarian 
tumors. (A) Overexpression of erbB2 in SKOV3ip ovarian tumor xeno-
grafts was confirmed by erbB2 staining (a-erbB2 staining, b-negative 
control). B) MSC-GFP and MSC-AR labeled with firefly luciferase were 
injected ip in SCID mice bearing SKOV3ip1 ovarian tumor xenografts at 
2x106 cell/mouse. Tumors were collected after 24 hrs and luciferase ex-
pression was measured in luciferase analysis. Data are presented as 
MSC numbers per mg protein in tumor homogenates.Komarova et al. Journal of Ovarian Research 2010, 3:12
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5D). Increased tumor/liver ratio indicates an increased
specificity of MSC-AR tumor targeting.
Discussion
A growing number of studies utilize engineered MSCs as
a tool to track malignant tissues and deliver anticancer
agents within the tumor microenvironment. MSC hom-
ing to tumors has been confirmed in a variety of experi-
mental models, however the homing efficiency is clearly
model-dependent and generally modest [3,10]. Addi-
tional cell targeting efforts may enhance the efficiency of
tumor homing and consequently deliver more therapeu-
tics. These cell targeting efforts may include physical cell
routing, utilization of physiological forces for cell concen-
tration and strategies that involve intrinsic or engineered
cell homing/targeting mechanisms [40]. Targeting strate-
gies can be used singly or in combinations to maximize
cell vehicle concentration in the target site. For instance,
combined native MSC tumor homing with precondition-
ing of the tumor site by irradiation has been shown to
enhance MSC homing to irradiated tumors [41]. Native
cell homing can also be combined with other types of cell
targeting means [42]. The current study investigated
whether native tumor targeting of MSCs can be enhanced
by engineered targeting via expressing an artificial tumor-
binding receptor.
Our study applied affinity-based targeting to cell vehi-
cles that lack immune recognition. T o date, only a few
applications have demonstrated the feasibility of using
scFvs as binding moieties in non-immune cell contexts.
One example is where an artificial chimeric receptor was
applied to primary human monocytes to target mono-
cytes to CEA-expressing tumor cells [25]. Another study
used gpi-anchored anti-CD20 scFv fragments exposed on
red blood cells (RBC) and evaluated binding of targeted
erythrocytes to CD20 positive tumors [26]. In our in vitro
experiments, MSCs grafted with anti-erbB2 artificial
receptors demonstrated increased binding to cells over-
expressing erbB2 (40% in experimental group versus 8%
in control). The only available study that investigated
Figure 5 Kinetics of MSCs homing to erbB2-expressing ovarian tumors. MSC-GFP and MSC-AR labeled with firefly luciferase were injected ip in 
SCID mice bearing SKOV3ip1 ovarian tumor xenografts at 2×10^6 cell/mouse. Tumors were collected at 4, 8, 24, 48 hrs and luciferase expression was 
measured by imaging of excised tumors (A) and by luciferase assay of tumor lysates (C). Representative photographs of mouse organs (B, upper panel) 
and the same organs with overlaid bioluminescent signal (B, lower panel) are presented. Arrows connect black and white image of organ and corre-
sponding image of the same organ with superimposed bioluminescent signal (D) Ratio of MSC numbers detected in tumor versus liver were deter-
mined for mice euthanized after 24 hrs after MSC injection. White bar is tumor/liver ratio for MSC, black bar is tumor/liver ratio of MSC-AR.Komarova et al. Journal of Ovarian Research 2010, 3:12
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similar erbB2-based cell binding interactions [28]
reported increased cell binding numbers that are in a
good agreement with our results (20% in experimental
group compared to 6-8% in control).
The next important question was whether the
enhanced MSC-AR binding ability would translate to an
in vivo tumor localization advantage, compared to
unmodified cells. Given complexity of the processes of
biodistribution and homing of injected cells, we reasoned
that an effect of engineered cell targeting would be more
pronounced and better detectable in model systems. For
instance, an isolated heart model was used to detect the
difference of MSC homing to normal versus infarcted
myocardium [43]. Thus, for initial testing we choose a
transient transgenic mouse model previously used to vali-
date targeting of the affinity-modified adenoviral vectors
[44]. Expression of erbB2 tumor marker in the mouse
lungs ensures its easy accessibility to systemically injected
cells and direct cell-marker contact. In addition, this
model allows the dissection of only the affinity-related
component of cell targeting, since native homing of MSC
to lungs has not been reported. Of note, this model is eas-
ily manipulated whereby other markers can be tested in
similar fashion.
It is not accidental that most studies detecting tumor
homing of intravenously introduced MSC were per-
formed on lung tumor models [4,10,13,45,46]. This mode
of cell introduction utilizes two cell-targeting mecha-
nisms, temporal physiological accumulation of cells in the
lungs and native MSC tumor homing, whereby lung-con-
centrated MSCs actively migrate to local lung tumors. It
was expected that accumulation of MSC in the lungs after
systemic injection would be the same for modified and
unmodified MSCs due to the first-pass effect [39]. How-
Figure 6 Biodistribution of MSC-GFP and MSC-AR to the major organs in SKOV xenograft bearing mice after ip injection. Tumors, liver, 
spleen, kidney, intestine, heart/lung were collected at 2 hr (upper panels) and 24 hr (lower panels) after MSC-GFP or MSC-AR injections. MSC biodis-
tribution was detected by bioluminiscent imaging of excised organs and presented as average signal intensity per area of each organ.Komarova et al. Journal of Ovarian Research 2010, 3:12
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ever, AR-expressing cells by virtue of enhanced cell-cell
interactions may show different levels of cell retention
and kinetics of subsequent lung evacuation. In two subse-
quent experiments we have shown that MSC and MSC-
AR have a different pattern of interaction with erbB2-
lungs. An increased number of MSC-AR was detected in
the lungs at several time points compared to MSC num-
bers. The time window, where the differences in experi-
mental groups were detectable, was relatively short (14-
32 hrs). At more distant time points (52, 72 hrs) MSCs
were not detected in the lungs using this method. We
believe that the major reason for this is MSC destruction.
The hCAR transgenic mice are immunocompetent and
xenogeneic (human) MSCs introduced into immuno-
competent mice are likely to be killed by immune-based
mechanisms over time. Despite the short window of
opportunity for detecting differences, this model, never-
theless, gave us an indication that modified cells have dif-
ferent behavior in the model system and in vivo cell-cell
interactions result in a detectable cell retention effect.
A more relevant and stringent model to test potential
benefits of additional MSC targeting is the ovarian tumor
model. We have previously demonstrated the native abil-
ity of MSC to home to SKOV3ip1 xenografts [12]. The
high level of erbB2 expression makes the SKOV3ip1
model appropriate to test our double-targeting strategy,
which engages both mechanisms of MSC-AR tumor tar-
geting: native and engineered. Multiple primary and met-
astatic tumor nodules with generally poor developed
stromal structures may again offer better accessibility of
tumor markers to cell vehicles expressing AR and allows
the detection of the benefit of affinity-based targeting. In
the pilot experiment, a substantial increase (8-folds) in
the number of tumor -associated MSC-AR versus MSC
was detected. To validate this initial observation and to
more accurately establish the timing of MSC homing, we
investigated the kinetics of MSC tumor targeting. The
speed and pattern of cell vehicles homing to target sites
are important parameters to consider in designing thera-
peutic delivery strategies, as these values may differ con-
siderably. For instance, homing of systemically injected
CD34+ cells to bone marrow is very fast; these cells reach
the bone marrow in 1 hr [47]. However, there is not much
data on the efficiency and speed of MSC homing to
tumors. Upon systemic injection MSC tumor homing is
apparently delayed and diminished due to trapping in the
lung vasculature. It is reported that upon systemic injec-
tion, MSC can stay in the lungs for two or more days
[7,48], thus the intravenous route of MSC introduction is
slow and inefficient. Recent quantitative studies found
less than 1% of systemically injected MSC is able to reach
distant sites [49,50]. In the ip tumor settings, MSCs did
not have to pass the lungs, thus the anticipated time for
MSC tumor homing is expected to be much shorter and
efficiency better. Despite this prediction, the actual kinet-
ics of MSC homing was unknown. In our experiment, we
detected preferential homing of MSCs to tumors as early
as 2 hrs, while the maximum homing of MSCs to ovarian
tumors was observed at 24 hrs after cell injection. The
k i n e t i c s  o f  h o m i n g  i s  a n  i m p o r t a n t  p a r a m e t e r  f o r  o u r
fu t u r e  s t r a t egy  o f  us i n g  MSC - bas ed  v e h i c l e s  t o  d e l i v e r
oncolytic adenoviruses. Quick homing ensures that cells
have enough time to reach tumors before they are killed
by virus replication.
We detected preferential tumor localization of MSCs in
both MSC and MSC-AR groups, which confirmed the
native tumor homing abilities of these cells and assured
that these functions are not perturbed by AR expression.
In two separate experiments we detected an increase in
the number of tumor-associated MSC-AR versus MSC-
GFP starting from 24 hrs using two methods of luciferase
quantitation.
The analysis of MSC distribution in the peritoneum
demonstrated that intraperitoneally developed tumors
are the major cell homing sites in both groups and across
all time points tested. The ability to localize to even
minor tumor metastasis at the surface of organs is a
remarkable property of MSCs that can be exploited for
diagnostic or treatment endpoints. Although addition of
the AR might not influence the actual process of MSC
moving towards a chemotactic homing gradient, it was
able to "strengthen" binding to tumors and resulted in
increased tumor-associated cell numbers and the tumor/
liver ratio. The mechanism of these effects is potentially
mediated by increased adherence to tumor cells, which
affected both the efficacy (number of cells attached to
tumors) as well as the specificity (ratio of tumor-bound
versus other organ bound cells).
In both models we capitalized on the accessibility of
targeting tumor markers to cells expressing AR. The
necessity of the accessibility may dictate a careful selec-
tion of the marker and corresponding targeting moiety.
For instance, under systemic injection, circulated cells are
most likely to have physical contact with endothelial cells,
supporting the targeting of specific endothelium markers.
Such selective binding of circulating cells to key neovas-
culature markers has been described [51,52]. An avenue
for utilizing tumor markers may be facilitated by irregular
and atypical tumor vasculature allowing direct contact of
circulating cell vehicles with tumor cells. Further studies
to identify such markers and to test if cell targeting to
these markers increases their retention in tumors are
needed.
Another important issue concerning the therapeutic
use of cells as vehicles is the quantity of cells reaching the
desired destination, as well as an understanding of how
these numbers translate to therapeutic benefits. Some
applications might need a maximum possible cell numberKomarova et al. Journal of Ovarian Research 2010, 3:12
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to achieve a therapeutic benefit [6,7,53], while others may
benefit from delivery just a few cells to trigger the desired
effect [45]. Thus, knowledge of the quantitative charac-
teristics of cell homing in different models is useful and
needed for further translation of these strategies to the
clinic.
The majority of studies exploiting MSC tumor homing
have only demonstrated the presence of labeled MSCs in
the tumor parenchyma [8,11,13,29]. The quantitative
aspect of cell homing or targeting to some extent is pres-
ent in the available literature, however, it is not usually
the major subject of these studies and, therefore, is not
systematically approached. Meaningful information on
homing efficiency can only be extracted when compari-
sons are performed within the same study. For instance,
such comparisons are reported on different routes of
MSC injection [54] or homing of MSC to non-irradiated
versus irradiated tumors in single animal [41,55] or com-
paring MSC and 3T3 tumor homing [9].
Among the studies that attempted quantitation of MSC
numbers in particular sites, only moderate cell numbers
in the targeted tissues were reported [3,10]. MSC num-
bers in these studies are mostly expressed as relative
units, thus, preventing the calculation of the actual hom-
ing efficiencies as a proportion of the injected cell dose.
To date, most studies attempting MSC quantitaion were
performed on lung tumors or lung metastases. Despite
moderate cell numbers in lung tumors reported, these
studies demonstrated the therapeutic effect of local cell-
based transgene delivery. This is an important observa-
tion, as it demonstrates that even moderate cell numbers
in lung tumors are sufficient to show a therapeutic bene-
fit to this approach. Studies investigating MSC homing to
distant (subcutaneous) tumors after systemic injection
reported more controversial numbers [5]. While the pres-
ence of MSCs in subcutaneous tumors after iv introduc-
tion in general was demonstrated, only one study has
reported on the therapeutic efficacy of MSC-based deliv-
ery to sc tumors [8]. The benefits of therapeutic treat-
ment in such settings remain to be proved. Thus, despite
the fact of the recruitment of MSC to tumors has been
established in a variety of experimental models, the effi-
cacy of this process in each case varies and is still presents
a subject for investigation.
The major purpose of our study was to investigate the
differences that AR-modified cells achieve in tumor tar-
geting. Therefore, thorough quantitative evaluation of
absolute cell numbers per tumor or other organs was not
performed. Of note, some features of the ovarian tumor
model influence accurate quantitative estimation of
tumor cell homing and have to be accounted for. Multiple
tumor nodules and metastasis hamper accurate collec-
tion of the entire tumor sample, which results in underes-
timation of total MSC tumor homing levels. On the
contrary, metastases to organs (spleen, liver, intestine
surfaces), if not identified and dissected out, may incor-
rectly attribute MSC homing to these organs, especially
u s i n g  b u l k  a s s a y s  s u c h  a s  l u c i f e r a s e  a c t i v i t y  o f  o r g a n
lysate. This leads to an overestimation of MSC distribu-
tion to off-tumor sites, while, in fact, this is also tumor-
related homing. Therefore, accurate quantitative analysis
would require more attention to both, the procedure of
organ collection for analysis, and the ability to better
visualize tumor nodules.
Nevertheless, the importance of quantitative assess-
ment, as well as developing an accurate methodology for
determination of absolute cells numbers in organs has
been recognized. Thus, tumor homing data were pre-
sented as cells per mg of protein, which gives a ballpark
estimation of cell numbers present in tumors at these
conditions. The level of native MSC tumor targeting was
roughly estimated as 10% of the injected cell dose, while
addition of the artificial receptor increased this efficiency
1.5-2 times. Based on this estimation, we believe that
MSC-based therapeutic delivery has more practical util-
ity after tumor debulking. In the residual disease it may
provide much higher vehicle/tumor cell ratio than cases
in which large primary tumors exist. Also, a marker tar-
geted by MSC-AR will be better exposed on small tumor
nodules without prominent stromal component or on
patches of disseminated tumor cells.
Conclusions
Our study confirmed that modification of cell carriers via
expressing artificial receptor mediates the numbers of
injected cell carriers in the organ or site of interest. We
have demonstrated the practical relevance of our strategy
in an ovarian tumor model, and showed that the number
of modified MSC carriers increased in intraperitoneal
tumors. Artificial receptor strategy can be applicable to
other cell types, especially to circulating cells lacking
native homing abilities.
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